Immediate Evaluation for Deep Vein Thrombosis
This patient requires urgent evaluation with duplex ultrasound of the left lower extremity to rule out deep vein thrombosis (DVT), given the 8-day history of ankle pain and swelling in the setting of recent stroke and anticoagulation with rivaroxaban.
Clinical Assessment Priority
The combination of unilateral leg swelling, pain, and a history of stroke (indicating prior thromboembolic disease) creates high suspicion for DVT despite being on anticoagulation. The key question is whether this represents:
- Anticoagulation failure (inadequate dosing or drug interaction)
- New thrombosis despite appropriate anticoagulation
- Alternative diagnosis (cellulitis, trauma, venous insufficiency)
Immediate Diagnostic Steps
1. Confirm DVT Status
- Duplex ultrasound of left lower extremity - perform urgently
- Assess for extent of thrombosis (calf vs. proximal)
- Evaluate for propagation into proximal veins or IVC
2. Verify Anticoagulation Adequacy
Critical medication review:
- Confirm rivaroxaban dose (should be 20 mg daily for stroke prevention, or 15 mg daily if creatinine clearance 30-49 mL/min) 1
- Check for drug interactions - particularly important as carbamazepine and other strong CYP3A4 inducers can significantly reduce rivaroxaban levels, potentially rendering anticoagulation insufficient 2
- Assess compliance - when exactly did patient restart Xarelto? Was there a gap in therapy?
- Review timing of doses
3. Assess Bleeding Risk vs. Thrombotic Risk
- Check complete blood count, renal function (creatinine clearance)
- Evaluate for any signs of bleeding
Management Algorithm
If DVT is Confirmed:
Scenario A: Patient on appropriate rivaroxaban dose with good compliance
- Consider rivaroxaban treatment failure 3
- Switch to alternative anticoagulation - warfarin or LMWH bridging may be more effective in this patient 3
- Increase rivaroxaban to treatment dose (15 mg twice daily for 3 weeks, then 20 mg daily) if continuing rivaroxaban
Scenario B: Subtherapeutic anticoagulation identified
- Drug interaction present (especially CYP3A4 inducers): Avoid rivaroxaban, switch to warfarin 2
- Dosing error: Correct to appropriate dose
- Non-compliance: Address barriers, consider supervised therapy
Scenario C: Recent gap in anticoagulation
- Initiate treatment-dose anticoagulation immediately
- For acute DVT: Rivaroxaban 15 mg twice daily for 21 days, then 20 mg daily 4
- Alternative: LMWH bridge to warfarin if concerns about rivaroxaban efficacy
If No DVT Found:
Evaluate alternative causes:
- Cellulitis (look for erythema, warmth, fever)
- Chronic venous insufficiency
- Trauma or musculoskeletal injury
- Continue stroke-prevention dose anticoagulation
Critical Pitfalls to Avoid
Do not assume anticoagulation is adequate - rivaroxaban can fail, particularly with drug interactions 2, 3
Do not delay imaging - 8 days of symptoms with stroke history warrants urgent evaluation
Check for CYP3A4 inducers - these dramatically reduce rivaroxaban efficacy and are contraindicated for concomitant use 2
Consider switching anticoagulants if DVT confirmed on rivaroxaban - case reports demonstrate warfarin success after rivaroxaban failure 3
Verify stroke indication - if patient has atrial fibrillation, ensure appropriate stroke prevention dose is being used 1
Specific Anticoagulation Guidance for This Patient
Given prior stroke, the patient requires lifelong anticoagulation 1. If DVT is confirmed while on rivaroxaban, this represents anticoagulation failure and warrants either dose escalation or switch to alternative agent 3. The 2021 AHA/ASA guidelines support use of rivaroxaban for stroke prevention in AF 1, but treatment failure requires reassessment of the anticoagulation strategy.
For acute DVT treatment (if confirmed): Consider LMWH followed by warfarin rather than continuing rivaroxaban, given evidence of potential treatment failure 3, 4.